TopoTarget A/S
Symbion
Fruebjergvej 3
2100 København
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
To OMX, Investor news
Investor News No. 3-07 / Copenhagen, 12 October 2007
TopoTarget Expands Investor and Public Relations Department
Copenhagen, Denmark, 12 October 2007 - TopoTarget (OMX: TOPO) is pleased to
announce that Rachel Curtis Gravesen has been appointed as Vice President
International Investor and Public Relations (IR & PR) as part of the company's
strategy to strengthen communication with the domestic market and to increase
focus on communication with the international business community.
“Rachel brings valuable experience and skills from the world of biotechnology
business communication. TopoTarget is committed to high quality communication
with the business and financial community and Rachel's appointment is an
important part of our ongoing Investor and Public Relations strategy as we
continue to build a business,” says Peter Buhl Jensen, CEO of TopoTarget.
Previously, Rachel ran the IR & PR Department at Genmab A/S and most recently
founded the IR & PR department at LifeCylePharma A/S. Rachel has broad
experience working as a journalist and in financial communication, having
worked at the BBC in the UK and as Nordic Editor at CNBC in Europe.
Rachel has a BA and MA from the University of Cambridge and a Postgraduate
qualification in Journalism from City University in London.
Rachel will work together with Ulla Hald Buhl, Director of IR and
Communications.
TopoTarget A/S
For further information, please contact:
Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Rachel Curtis Gravesen Mobile +45 25 12 62 60
Vice President, International IR and PR
Ulla Hald Buhl Mobile +45 21 70 10 49
Background information
About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with
subsidiaries in US, Switzerland, Germany and the UK, dedicated to finding
''Answers for cancer'' and developing improved cancer therapies. TopoTarget is
founded and run by clinical cancer specialists and combines years of hands-on
clinical experience with in-depth understanding of the molecular mechanisms of
cancer. Focus lies on highly predictive cancer models and key cancer targets
(including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and a
strong development foundation has been built. TopoTarget has a broad portfolio
of small molecule pre-clinical drug candidates and eight drugs (both small
molecules and protein based) are in clinical development, including both novel
anti-cancer therapeutics and new cancer indications for existing drugs.
Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is
TopoTarget's first product on the market. For more information, please refer to
www.topotarget.com.
TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by law.
